
Biogaia AB
STO:BIOG B

Biogaia AB
Revenue
Biogaia AB
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Biogaia AB
STO:BIOG B
|
Revenue
kr1.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
![]() |
Bonesupport Holding AB
STO:BONEX
|
Revenue
kr997.9m
|
CAGR 3-Years
62%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
![]() |
Vitrolife AB
STO:VITR
|
Revenue
kr3.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
19%
|
CAGR 10-Years
21%
|
|
![]() |
Probi AB
STO:PROB
|
Revenue
kr630.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
18%
|
|
![]() |
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Revenue
kr26B
|
CAGR 3-Years
19%
|
CAGR 5-Years
13%
|
CAGR 10-Years
26%
|
|
![]() |
BioArctic AB
STO:BIOA B
|
Revenue
kr257.4m
|
CAGR 3-Years
123%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
Biogaia AB
Glance View
BioGaia AB engages in the development, marketing, and sale of probiotic products. The company is headquartered in Stockholm, Stockholm. The firm develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The firm operates worldwide.

See Also
What is Biogaia AB's Revenue?
Revenue
1.4B
SEK
Based on the financial report for Dec 31, 2024, Biogaia AB's Revenue amounts to 1.4B SEK.
What is Biogaia AB's Revenue growth rate?
Revenue CAGR 5Y
13%
Over the last year, the Revenue growth was 10%. The average annual Revenue growth rates for Biogaia AB have been 22% over the past three years , 13% over the past five years .